Robot-Assisted Right Colectomy with Sequential Wedge Resection of Segments 4 and 5 of The Liver and Cholecystectomy for Colon Cancer with Metastasis to The Liver.

The liver is the most common place for colon adenocarcinoma metastasis because of portal circulation. The surgical intervention for patients with colon adenocarcinoma with synchronous metastasis to the liver has been debated. Studies have shown that the simultaneous resection of a colorectal adenocarcinoma with a liver metastasis has similar outcomes compared to the traditional staged approach when looking at morbidity, mortality, and long-term oncologic effects. There has also been a shift to less invasive procedures when performing abdominal surgery. However, the laparoscopic method that has increasingly been used for the simultaneous procedure is technically challenging and therefore not widely adopted. The technical limitations hindering the simultaneous method could be overcome by utilizing a robotic approach. The aim of this report is to demonstrate the effectiveness of a robotic approach for colon adenocarcinoma with synchronous liver metastases.

Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles.

BACKGROUND: Neuroblastoma is one of the most challenging malignancies of childhood, being associated with the highest death rate in paediatric oncology, underlining the need for novel therapeutic approaches. Typically, patients with high risk disease undergo an initial remission in response to treatment, followed by disease recurrence that has become refractory to further treatment. Here, we demonstrate the first silica nanoparticle-based targeted delivery of a tumor suppressive, pro-apoptotic microRNA, miR-34a, to neuroblastoma tumors in a murine orthotopic xenograft model. These tumors express high levels of the cell surface antigen disialoganglioside GD2 (GD(2)), providing a target for tumor-specific delivery. PRINCIPAL FINDINGS: Nanoparticles encapsulating miR-34a and conjugated to a GD(2) antibody facilitated tumor-specific delivery following systemic administration into tumor bearing mice, resulted in significantly decreased tumor growth, increased apoptosis and a reduction in vascularisation. We further demonstrate a novel, multi-step molecular mechanism by which miR-34a leads to increased levels of the tissue inhibitor metallopeptidase 2 precursor (TIMP2) protein, accounting for the highly reduced vascularisation noted in miR-34a-treated tumors. SIGNIFICANCE: These novel findings highlight the potential of anti-GD(2)-nanoparticle-mediated targeted delivery of miR-34a for both the treatment of GD(2)-expressing tumors, and as a basic discovery tool for elucidating biological effects of novel miRNAs on tumor growth.